NEW YORK (GenomeWeb) – Trovagene announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Illinois, establishing access for plan members to the company's full line of Trovera liquid biopsy tests.

This product line currently includes assays performed on either blood or urine, which detect mutations in EGFR, KRAS, and BRAF.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.